Form 4: Xenon Pharmaceuticals Director Steven Gannon Acquires Stock Options

Director Steven Gannon acquired stock options in Xenon Pharmaceuticals, signaling a potential increase in his stake in the company.

Summary

• Steven Gannon, a director at Xenon Pharmaceuticals Inc., acquired stock options on June 5, 2024.
• The options grant him the right to buy 15,542 common shares at a price of $38.16 per share.
• The options vest on the earlier of June 4, 2025, or the day before the issuer's 2025 annual meeting of shareholders and expire on June 4, 2034.
• Following the transaction, Gannon directly owns 15,542 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider acquisition of stock options can be seen as a vote of confidence, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive signal.

Key Dates